Illumina CEO Predicts Routine Tumor Sequencing, Infant Genome Screening within Next Decade | GenomeWeb

By Julia Karow

As the cost of human whole-genome sequencing declines, it is increasingly applied to study and diagnose disease. At the Consumer Genetics conference in Boston last week, Illumina CEO Jay Flatley made a number of predictions of where the technology and the consumer genetics industry are headed.

Sequencing will start to be applied clinically and save lives, which he said is "actually happening here and now," but will grow in the future.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.